Target intelligence / Profile preview

Nuclear factor interleukin 3 regulated protein (NFIL3)

Target
NFIL3
Molecular classification
Transcription factor, Basic leucine zipper (bZIP) protein, CCAAT/enhancer-binding protein (C/EBP) family member
01

Overview

Nuclear factor interleukin 3 regulated protein (NFIL3, E4BP4) is a basic leucine zipper (bZIP) transcription factor crucial for differentiation and survival of immune cells, modulation of circadian rhythms, and neuroprotection. Structurally, NFIL3 contains a bZIP DNA-binding domain that dimerizes via a leucine zipper, binding specifically to the TTACGTAA DNA motif to regulate gene expression. NFIL3 represses genes involved in apoptosis, aiding cell survival, and has established roles in cancer progression (notably breast and colon cancer), as well as neuroprotection in models of ALS and other neurodegenerative diseases. It is also involved in the differentiation and maintenance of innate lymphoid cells (ILCs), which are key regulators of immune responses. While there is significant therapeutic interest, NFIL3 remains largely "undruggable" by conventional means, though approaches targeting its dimerization or DNA binding interfaces are in early investigation.

Other names
E4BP4NFIL3nuclear factor interleukin 3 regulated proteinbasic leucine zipper transcription factor NFIL3E4 promoter binding protein 4
02

Biological functions

Regulation of immune cell differentiationCircadian rhythm modulationNeuron survival and regeneration, neuroprotectionCell survival, apoptosis inhibitionSignal transduction (regulation of gene transcription)
03

Disease associations

Cancer (oncogenesis, resistance to apoptosis)Neurodegenerative disease (ALS/neuroprotection)Inflammation/Immunology (innate lymphoid cell differentiation, cytokine regulation)Potential role in metabolic/circadian disorders
04

Safety considerations

Targeting transcription factors may risk off-target effects and global alteration of gene expression programsNeuroprotection may interfere with physiological apoptosisCancer modulation—inhibiting apoptosis can contribute to tumorigenesis

Beyond the preview

Go deeper on Nuclear factor interleukin 3 regulated protein (NFIL3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuclear factor interleukin 3 regulated protein (NFIL3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call